https://allsci.com/news/licensing-and-partnerships/gsk-relation-collaboration-ai-drug-discovery/ AllScien 2026-07-30T18:52:27.739148Z Relation expands GSK collaboration to USD 110m with MORGAN foundation model for target discovery https://allsci.com/news/regulatory/enzomenib-orphan-drug-designation-fda-grants/ AllScien 2026-07-30T16:38:27.895802Z Sumitomo's enzomenib gets FDA orphan drug designation for ALL https://allsci.com/news/regulatory/ritlecitinib-vitiligo-pfizers-advances-to-become/ AllScien 2026-07-30T16:35:55.700950Z Pfizer's Litfulo succeeds in Phase III vitiligo trials, setting up rivalry with Rinvoq https://allsci.com/news/clinical-trials/cnd319-phase-i-trial-candid-initiates-of-dual/ AllScien 2026-07-30T16:18:51.760415Z Candid's trispecific CND319 enters first-in-human testing under UCB https://allsci.com/news/research/car-t-cell-toxicity-prediction-germline-variants/ AllScien 2026-07-30T16:18:34.200464Z Kite-backed study identifies inherited genetic predictors of CAR-T toxicity and expansion https://allsci.com/news/public-offerings/inovio-fda-decision-ino-3107-raises-usd-20m-ahead/ AllScien 2026-07-30T16:17:05.503962Z Inovio raises USD 20m ahead of make-or-break FDA decision on INO-3107 https://allsci.com/news/business/jj-firefly-bio-acquisition-kras-johnson-johnson/ AllScien 2026-07-30T16:16:55.457779Z J&J completes USD 1b Firefly acquisition to add pan-KRAS degrader capabilities https://allsci.com/news/pipe-financing/btk-inhibitor-acquisition-processa-acquires/ AllScien 2026-07-30T16:13:05.150734Z Processa acquires CNS-penetrant BTK inhibitor with USD 200m financing for three Phase II programs https://allsci.com/news/regulatory/deramiocel-fda-dmd-cardiomyopathy-advisory/ AllScien 2026-07-30T15:57:51.962487Z FDA advisory committee votes against Capricor's deramiocel effectiveness for DMD cardiomyopathy https://allsci.com/news/first-in-human-trials/oral-amylin-analog-verdiva-advances-first-with/ AllScien 2026-07-30T14:57:10.129253Z Verdiva advances oral amylin strategy with first-in-human study of VRB-103 https://allsci.com/news/regulatory/fda-clearance-iks04-adc-clears-iksudas-for-phase/ AllScien 2026-07-30T14:52:44.547134Z FDA clears Iksuda's CA242-targeted ADC for Phase I study in GI cancers https://allsci.com/news/clinical-trials/biogen-lupus-trials-2027-accelerates-and/ AllScien 2026-07-30T14:22:03.446931Z Biogen Q2'26: Lupus, AMR and Dravet catalysts take center stage https://allsci.com/news/research/mammarenavirus-inhibitor-development-scripps/ AllScien 2026-07-30T13:52:38.664251Z Scripps advances dual-target mammarenavirus antivirals with NIAID funding https://allsci.com/news/clinical-trials/caldera-taps-reverse-merger-to-advance-tl1a-x-il-23-bispecific/ AllScien 2026-07-29T17:17:16.972374Z Caldera taps reverse merger to advance TL1A × IL-23 bispecific https://allsci.com/news/venture-financing/adjuvia-raises-usd-8m-for-preclinical-stage-mitochondrial-therapy/ AllScien 2026-07-29T17:04:21.481730Z Adjuvia raises USD 8m for preclinical-stage mitochondrial therapy https://allsci.com/news/licensing-and-partnerships/abcellera-adds-vertex-as-latest-tce-platform-partner-in-autoimmune-disease/ AllScien 2026-07-29T16:51:36.452179Z AbCellera adds Vertex as latest TCE platform partner in autoimmune disease https://allsci.com/news/licensing-and-partnerships/qnovia-bets-on-antimicrobial-peptides-with-exclusive-uva-deal/ AllScien 2026-07-29T16:27:15.812498Z Qnovia bets on antimicrobial peptides with exclusive UVA deal https://allsci.com/news/funding/lb-pharma-raises-usd-150m-to-expand-lb-102-zinto-three-neuropsychiatric-indications/ AllScien 2026-07-29T16:15:58.867734Z LB Pharma raises USD 150m to expand LB-102 zinto three neuropsychiatric indications https://allsci.com/news/clinical-trials/hansohs-b7-h3-adc-set-for-china-filing-after-hitting-phase-iii-endpoint-in-osteosarcoma/ AllScien 2026-07-29T15:59:41.622724Z GSK/Hansoh's B7-H3 ADC set for China filing after hitting Phase III endpoint in osteosarcoma https://allsci.com/news/funding/shape-therapeutics-secures-funding-to-advance-one-time-gene-therapy-for-parkinsons-disease/ AllScien 2026-07-29T13:40:59.980831Z Shape Therapeutics secures funding to advance one-time gene therapy for Parkinson's disease. https://allsci.com/news/clinical-trials/gsk-accelerates-20-plus-phase-iii-starts-through-gbp-1-9b-savings-program/ AllScien 2026-07-29T13:27:47.985456Z GSK accelerates 20-plus Phase III starts through GBP 1.9b savings program https://allsci.com/news/funding/basilea-secures-usd-30m-barda-tranche-to-advance-fosmanogepix-phase-iii-trials/ AllScien 2026-07-29T11:15:57.466568Z Basilea secures USD 30m BARDA tranche to advance fosmanogepix Phase III trials https://allsci.com/news/regulatory/fda-clears-registrational-phase-ii-path-for-cullinans-cln-049-in-relapsed-refractory-aml/ AllScien 2026-07-29T09:08:33.994742Z FDA clears registrational Phase II path for Cullinan's CLN-049 in relapsed/refractory AML https://allsci.com/news/clinical-trials/ateas-hepatitis-c-combination-meets-non-inferiority-bar-clears-path-to-regulatory-filing/ AllScien 2026-07-29T09:05:26.168035Z Atea's hepatitis C combination meets non-inferiority bar, clears path to regulatory filing https://allsci.com/news/pharma/core-launches-with-a-portfolio-licensed-from-eisai-plus-usd-21m-in-financing/ AllScien 2026-07-29T08:47:31.994194Z CORE launches with a portfolio licensed from Eisai plus USD 21m in financing https://allsci.com/news/regulatory/fda-adcom-briefing-raises-broad-efficacy-concerns-over-replimunes-melanoma-bla/ AllScien 2026-07-29T08:40:23.917753Z FDA AdCom briefing raises broad efficacy concerns over Replimune's melanoma BLA